NASDAQ
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Poi...
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Secu...
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to ...
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen....
NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Secur...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Bioge...
MILWAUKEE, March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen. Click here to learn how to join our inv...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right...
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a definitive agreement under which Biogen has agreed t...
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a definitive agreement under which Biogen has agreed t...
No price data available for this timeframe.